Building Foundational mRNA Technology for Next-Generation Therapeutics

Providing reusable, verifiable, and scalable mRNA drug development and industrialization capabilities for complex and evolving disease challenges.

News

News

Platform milestones, partnership progress, and key updates.

Breakthrough | RNACure Co-Developed COVID-19 mRNA Vaccine Approved for Marketing
2026/9/10公司动态
Breakthrough | RNACure Co-Developed COVID-19 mRNA Vaccine Approved for Marketing
The COVID-19 mRNA vaccine co-developed by Fudan University, RNACure, Guangzhou Laboratory and Walvax Biotechnology received the Drug Registration Certificate from China's NMPA, becoming the first mRNA vaccine in China approved for marketing through iterative development on an mRNA platform technology strategy.
Learn more
Deepening Industry-Education Integration | RNACure & SUSTech Campus-Enterprise Exchange
2026/5/30公司动态
Deepening Industry-Education Integration | RNACure & SUSTech Campus-Enterprise Exchange
RNACure hosted a SUSTech student delegation for a campus-enterprise exchange focused on technology exchange, scientific research collaboration, and talent development.
Learn more
深化国际创新合作 共拓产业新局|芝加哥大学Polsky创新中心到访蓝鹊生物
2026/5/19国际合作
深化国际创新合作 共拓产业新局|芝加哥大学Polsky创新中心到访蓝鹊生物
芝加哥大学Polsky创业与创新中心核心团队到访上海蓝鹊生物,双方围绕跨境生物医药创新、技术转化、产业合作以及生态建设深入对接,共同探索国际化产学研协同创新新模式。
Learn more
聚焦全球产能共建 助力卫生公平|WHO董继萃博士一行到访蓝鹊生物交流调研
2026/3/13国际合作
聚焦全球产能共建 助力卫生公平|WHO董继萃博士一行到访蓝鹊生物交流调研
世界卫生组织(WHO)产品政策、可及性与生产支持单位(PAM)负责人董继萃博士一行莅临上海蓝鹊生物开展专项调研交流,聚焦WHO全球疫苗本地化生产、技术转移与健康公平发展目标。
Learn more
蓝鹊生物冻干带状疱疹mRNA疫苗(RQ3400)获国家药监局临床试验默示许可
2025/12/1研发进展
蓝鹊生物冻干带状疱疹mRNA疫苗(RQ3400)获国家药监局临床试验默示许可
蓝鹊生物与复旦大学、沃森生物合作开发的首款采用先进冻干制剂技术的冻干带状疱疹mRNA疫苗(RQ3400)获国家药监局临床试验默示许可,突破传统mRNA疫苗超低温储存瓶颈。
Learn more
Fudan Students Explore mRNA Innovation & Industrialization at RNACure
2025/11/19公司动态
Fudan Students Explore mRNA Innovation & Industrialization at RNACure
A class from Fudan University's core curriculum 'Biotechnology and Human Society' visited RNACure for an immersive learning experience on mRNA technology breakthroughs and industrialization.
Learn more
蓝鹊生物RSV mRNA疫苗(RQ3201)获CDE临床试验默示许可 实现中美双报
2025/10/15研发进展
蓝鹊生物RSV mRNA疫苗(RQ3201)获CDE临床试验默示许可 实现中美双报
继美国FDA IND获批之后,蓝鹊生物RSV mRNA疫苗(RQ3201)再获国家药品监督管理局药品审评中心(CDE)临床试验默示许可,成功实现「中美双报」战略目标。
Learn more
蓝鹊生物联合多家机构在《Vaccine》发表发热伴血小板减少综合征mRNA疫苗研究成果
2025/8/10研发进展
蓝鹊生物联合多家机构在《Vaccine》发表发热伴血小板减少综合征mRNA疫苗研究成果
蓝鹊生物与中国科学院武汉病毒研究所、复旦大学中山医院等合作,在国际疫苗学权威期刊《Vaccine》发表SFTSV mRNA疫苗研究成果,仅需1μg极低免疫剂量即可在动物模型中提供100%完全保护。
Learn more
面向全球健康的高可及性mRNA递送平台的研发|盖茨基金会莅临蓝鹊生物开展专项交流
2025/4/29国际合作
面向全球健康的高可及性mRNA递送平台的研发|盖茨基金会莅临蓝鹊生物开展专项交流
盖茨基金会代表团莅临上海蓝鹊生物开展专项技术交流,聚焦高可及性mRNA递送技术与全球传染病防控需求,围绕新型递送系统创新、传染病疫苗研发及产业化普惠应用开展深度对接。
Learn more
CAREERS

Careers

Transforming public health and tackling major diseases requires more than a single successful program—it takes an mRNA platform that can respond rapidly, manufacture reliably, and iterate continuously. That is why we are building long-term foundational capabilities with talent across molecular biology, delivery and materials, process development and QC, and clinical translation.

Join us to help make mRNA a global health infrastructure—accessible, scalable, and affordable for more people.

Floors 7–9, Building C7, Bay Valley Science and Technology Park, Yangpu District, Shanghai
Follow us
©2026 RNACure BioPharma. All rights reserved.